Baricitinib is a once daily, oral selective Janus kinase (JAK) inhibitor for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to 1 or more tumor necrosis factor (TNF) antagonist therapies. JAK inhibitors are small molecules that interrupt intracellular signaling pathways in the inflammatory cycle by inhibiting the activity of 1 or more of the JAK enzymes (JAK1, JAK2, JAK3, and tyrosine kinase 2). Because of their small size, they can be formulated for oral administration.

If you have a Hayes login, click here to view the full report on the Knowledge Center.